PT - JOURNAL ARTICLE AU - Wang, Zhiyin AU - Duan, Honglei AU - Wang, Yuan AU - Liu, Dan AU - Cao, Chenrui AU - Dai, Yimin AU - Zhao, Guangfeng AU - Gu, Ning AU - Zhou, Yan AU - Zheng, Mingming AU - Hu, Yali TI - Increased Circulating miR-155 identifies a subtype of preeclamptic patients AID - 10.1101/2022.03.23.22272742 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.23.22272742 4099 - http://medrxiv.org/content/early/2022/03/23/2022.03.23.22272742.short 4100 - http://medrxiv.org/content/early/2022/03/23/2022.03.23.22272742.full AB - Preeclampsia is a heterogeneous disorder which affect maternal and fetal outcomes. The current classifications of preeclampsia such as “early-“ and “late-” types, and “mild” and “severe” forms, are too imprecise to delineate the pathophysiology of preeclampsia. Here we reported that roughly one third of preeclampsia patients had high expression of maternal serum miR-155 in the case-control study and longitudinal study. The maternal serum miR-155 increased as early as 11-13+6 weeks of gestation. The patients with high serum miR-155 had severer clinical symptoms such as higher blood pressure and urine protein, and more adverse maternal and fetal outcomes. Moreover, these patients could be clustered as one group according to clinical manifestation by t-distributed stochastic neighbor embedding analysis. Therefore, these data suggest that preeclamptic patients with high maternal serum miR-155 could be viewed as a subtype of preeclampsia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Key R&D Program of China (2021YFC2701603); Jiangsu Provincial Key Medical Center (YXZXB2016004); National Natural Science Foundation of China (82071666); Jiangsu Biobank of Clinical Resources (BM2015004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of The Affiliated Drum Tower Hospital of Nanjing University Medical School gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript